Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00LSW
|
||||
| Former ID |
DIB013915
|
||||
| Drug Name |
VA-111913
|
||||
| Synonyms |
VA-111913 TS; VA-913; VT-913; V1a antagonists (dysmenorrhea), Vantia; Vasopressin 1a antagonists (dysmenorrhea), Vantia/Ferring
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Dysmenorrhea [ICD9: 625.3; ICD10:N94.4-N94.6] | Phase 2 | [1] | ||
| Company |
Ferring Pharmaceuticals Inc
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C23H21ClFN5O2
|
||||
| Canonical SMILES |
N1c2c(N(Cc3cnn(c13)C)C(=O)c1cc(c(cc1)CNC(=O)C1CC1)F)ccc<br />(c2)Cl
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Vasopressin V1a receptor | Target Info | Antagonist | [2] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Vascular smooth muscle contraction | |||||
| Reactome | Vasopressin-like receptors | ||||
| G alpha (q) signalling events | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00963053) VA111913 Dysmenorrhoea Efficacy and Safety Proof of Concept. U.S. National Institutes of Health. | ||||
| REF 2 | Clinical pipeline report, company report or official report of Avarx. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.